Screener
BioSig Technologies, Inc. STEX Q3 2026 earnings
Reported November 12, 2026 · After market close
Revenue$100.0KMiss by $155.0K
EPS-$0.09Miss by $0.06
Revenue estimate$255.0K
EPS estimate-$0.03
“Q1 launched GLDY, Q2 built the distribution around it, and Q3 was about scaling that distribution and adoption. Over the last ninety days, an institutional investment manager began running a gold carry strategy with GLDY as its long leg, outside ownership doubled, and the Cask Foundation began bootstrapping liquidity for its first product, USGY. Next week, GLDY goes live as the first tokenized asset on Equity Trust's IRA platform. This is not scale yet, but the drivers that can get us there are now live or under way.”
Next report
Date not yet announcedFinancials
Q3 2026Valuation & ratios
Versus estimates
Revenue
Q3 2026$100.0KMiss by $155.0K
Q2 2026$300.0KIn lineDiluted EPS
FAQ
- When did BioSig Technologies, Inc. report Q3 2026 earnings?
- BioSig Technologies, Inc. (STEX) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were BioSig Technologies, Inc.'s Q3 2026 revenue and EPS?
- BioSig Technologies, Inc. reported revenue of $100.0K and eps of $-0.09 for Q3 2026.
- Did BioSig Technologies, Inc. beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $255.0K by $155.0K. EPS missed the consensus estimate of $-0.03 by $0.06.
- How did BioSig Technologies, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 80.9% from $-0.47.
- Where can I find BioSig Technologies, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001493152-26-051389) and the 10-Q periodic report (0001493152-26-051398) directly on SEC EDGAR. The filing index links above go to sec.gov.
